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Short Communication
Interaction of diethylaminoreserpine with cells of a
transplantable tumour in vivo
S. Lehnert
Radiation Oncology, Montreal General Hospital, 1650 Cedar Ave., Montreal H3G IA4, Quebec, Canada.
The toxicity of diethylaminoreserpine (DL-152) to
cells of transplantable mouse tumours has been
investigated in this laboratory using in vivo and in
vitro systems (Lehnert, 1980, 1982a, 1982b). It was
found that for short exposures to DL-152, hypoxic
tumour cells are more sensitive to the drug than are
aerated cells, while in vitro hypoxic cells are killed
by lower concentrations of the drug than are
aerated cells. For both flank and lung tumours,
sensitivity to the drug increases with increasing
tumour size, however the presence of an hypoxic
fraction is not a prerequisite for the cytotoxic
action of the drug. These results support the
conclusion that hypoxia sensitises cells to the toxic
effects of DL-152 but is not essential for the
expression of toxicity. On this basis it was predicted
that although not a radiosensitiser per se (Lehnert
et al., 1981) DL-152 might be used effectively in
conjunction with radiotherapy, if administration
were timed to reduce the radioresistant hypoxic cell
population to a minimum prior to irradiation. In
the present study, the validity of this prediction was
investigated by measurement of the hypoxic
fraction of the KHT tumour at various times after
drug injection. In addition, the extent of cell kill
was correlated with the drug concentration in the
tumour.
DL-152 was obtained from Laboratoires Lefrancq,
Romainville, France. DL-152 (320mgkg -1)
was injected i.p. in 0.1 ml saline. Control mice were
injected with 0.1 ml saline and the tumour
processed in parallel with the DL-152 treated
group.
The KHT fibrosarcoma (Kallman et al., 1967)
was grown in male C3H mice. Tumours were
implanted intramuscularly by injection of 2.5 x 105
cells in a volume of 0.05ml into the distal portion
of the gastrocnemius muscle of one hind leg. The
colony forming ability of KHT cells was assayed by
the in vitro agar plating technique described by
Thomson & Rauth (1974) as modified by Hill et al.
(1979). Tumour size was determined by
measurement of the diameter of the tumour-bearing
leg. Values were converted to tumour weights by
reference to a previously prepared calibration curve
relating leg diameter to tumour weight.
The size of the hypoxic fraction was determined
for tumours of approximately 0.5g by comparison
of survival curves of tumours irradiated in situ in
air-breathing and nitrogen-asphyxiated mice, a
method originally described by Van Putten &
Kallman (1968). Straight lines on a semi-log plot
were fitted to data points between 15 and 30Gy by
linear regression analysis. The hypoxic fractions
were calculated from the displacement of the
terminal portions of the survival curves for tumour
cells from air-breathing and nitrogen-asphyxiated
animals. The actual value assigned to the hypoxic
fraction was the ratio of Surviving Fractions at
25Gy using values read off the regression line.
For extraction of DL-152, the tumour was
homogenized in 7vol of 0.01 NHC1 and the
supernatant extracted with 4vol of chloroform, the
chloroform phase was washed twice with dilute acid
and evaporated to dryness. The efficiency of this
extraction procedure was -70%. The residue was
dissolved in a small volume of methanol and 20pl
samples chromatographed using a chromosorb C-18
column; the mobile phase was 60% acetonitrile,
37.5% water, 2.5% glacial acetic acid and 1.5gl-1
heptane sulfonic acid. Propriophenone was used as
an internal standard.
Reduction in the number of clonogenic cells per
tumour following administration of DL-152 to the
host resulted from two factors: a reduction in the
number of viable cells recovered from the tumour
and a decrease in the plating efficiency of these
cells. These two effects are shown separately in
Figures l(a) and l(b), while the overall reduction in
numbers of clonogenic tumour cells following DL-
152 injection is shown in Figure l(c).
It is apparent that reduction in the number of
cells recovered is the major factor in reducing
tumour cell numbers. Also shown in Figures l(a),
1(b) and 1(c) are results obtained when tumour
bearing animals are sacrificed by nitrogen
asphyxiation and excision of the tumour is delayed
for 15min after sacrifice. At all times after drug
injection, this period of acute hypoxia enhances the
cytotoxic effects of the drug and again the effect is
produced largely by reduction of the number of
viable cells recovered.
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Figure 1 (a) Changes in number of viable cells
recovered from KHT tumours at various times after
DL-152 injection (320mgkg-1). (0), tumour excised
immediately after sacrifice by cervical fracture. (0),
Tumour excised 15min after sacrifice by nitrogen
asphyxiation. Vertical bars represent s.e.m. each point
is mean of 5-6 assays. (b) Changes in plating efficiency
of viable cells recovered from KHT tumours at various
times after DL-152 injection (320mgkg-1). Conditions
of experiment and symbols as for (a). (c) Changes in
numbers of clonogenic cells recovered from KHT
tumours at various times after DL-152 injection
(320mgkg-1). Conditions of experiment and symbols
as for (a). Concentration of DL-152 in KHT tumour at
various times after i.p. injection (4.5 x 10-5molkg-1).
Cytotoxic agents whose primary target is DNA
(such as ionizing radiation) cause immediate loss of
proliferative potential in exposed cells but produce
no rapid changes in the visible indices of viability
such as cell lysis or loss of ability of the cell to
exclude Trypan Blue. Thus it seems unlikely that
the major site of action of DL-152 is the genetic
material of the cell. A possible site of action could
be the cell membrane, however, on the basis of
these results, it cannot be determined if membrane
damage might result from a direct effect of the drug
or be secondary to lesions at other intracellular
sites. Hypoxic cells, both in vivo and in vitro, are
more sensitive to the action of the drug which
suggests that inhibition of processes such as
glycolysis, essential to the survival of hypoxic cells,
might be involved.
In Figure l(d) the concentration of DL-152 in
the tumour at various times after intraperitoneal
injection of the drug (320mgkg- or 4.5 x
10-4Mkg-1) is shown. Maximum concentration
in the tumour (approximately 3.5x 10-5M) is
reached by I h after injection, this level persists for
up to 24h after which a gradual decline in
concentration is seen. It is apparent from Figure
1(c) that although the most rapid fall in tumour cell
numbers occurs during the first hour after drug
administration, a decline in cell number continues
for at least 24h after injection. This prolonged
period over which the effects of the drug persist is
presumably related to the slow rate at which DL-
152 is cleared from the tumour. Metabolism of DL-
152 may resemble that of reserpine in some
respects, following the injection of the latter
compound, low concentrations of the drug are
maintained in various tissues over a prolonged
period (Stitzel, 1976). It is unlikely that the
metabolism of DL-152 resembles that of reserpine
in all respects however, since the presence of a
polar side chain on DL-152 would presumably
reduce the high lipophilicity which characterizes
reserpine.
The preferential toxicity of DL-152 towards
- hypoxic cells which had been demonstrated in vivo
and in vitro suggested that reduction in the size of
the hypoxic fraction would occur in tumours
exposed to the drug. To test this hypothesis
radiation survival curves for aerated and hypoxic
KHT tumour cells irradiated in situ were prepared.
For controls (Figure 2) the ratio of Surviving
Fractions for the terminal portion of the survival
curves for aerated and hypoxic cells was 0.11,
giving an hypoxic fraction of 11% for 0.5g
intramuscular tumours. Figure 3 shows results
obtained at one hour after injection of 152; at
this time, both aerated and hypoxic cells show
higher survival (relative to drug treated controls)
than do cells from control tumours.
Radioprotection at short times after DL-152
injection has been previously observed for flank
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tumours and attributed to elevation of cyclic AMP
content of the tumour at the time of irradiation
(Lehnert et al., 1981). It should be noted that while
the Surviving Fraction for DL-152 treated tumour
cells relative to drug treated non-irradiated cells is
elevated, the overall number of clonogenic cells at
this time is reduced (see Figure 1). The hypoxic
fraction for tumours at one hour after DL-152
injection was calculated to be 15%, larger than that
of control.
At 8, 16, and 24h after DL-152 injection (Figure
4) results are not complicated by drug-induced
changes in radiation response, and at all three times
there is a decrease in the size of the hypoxic
fraction, the lowest value (4%) being seen at 8h
after injection. The sizes of the hypoxic fractions for
tumours assayed at various times after DL-152
injection are summarized in Table I.
Dose (Gy)
Figure 2 Survival curves for KHT tumour cells
irradiated in situ and assayed in vitro. (0) mice
irradiated while breathing air. (0) mice sacrificed by
nitrogen asphyxiation 5min before start of irradiation.
Vertical bars represent s.e.m., each point is the mean
of 3-4 assays.
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Table I Size of the hypoxic fraction of KHT
tumours at various times after injection of DL-152
(320jigkg-1, i.p.)
Time after DL-152 injection Hypoxicfraction
(h) +s.e. (%)
Control 11 + 1.7
1 15+1.8
8 4+0.05
16 5+1.7
24 6.5+2.2
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Figure 3 As Figure 2. Mice sacrificed 1 h after
injection of DL-152.
Table II gives a sample of the data on which the
calculation of hypoxic fraction is based. This is
included as an indication that the changes in
hypoxic fraction reported represent a reduction in
the proportion of hypoxic cells and are not a
consequence of undefined interactions between
hypoxia, drug, radiation and the mode of tumour
disaggregation. The first part of Table II is for non-
drug treated cells. There are no significant
differences (P>0.2) between cell yields for
aerated/hypoxic and irradiated/non-irradiated
tumours. Plating efficiency is reduced by radiation,
the extent of the reduction being dependent on
whether the tumour is hypoxic. The values in the
second part of Table II are for tumour 16h after
the injection of DL-152. The cell yield and plating
efficiency is reduced in comparison with non-drug
treated tumours as previously described. Again cell
yield is not affected by radiation just prior to
excision of the tumour. The Surviving Fraction is
calculated as the ratio of Plating Efficiencies of
irradiated/non-irradiated cells under hypoxic or
aerated conditions. The Surviving Fraction for
irradiated hypoxic cells from drug-treated tumours
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Figure 4 As Figure 2. Mice sacrificed 8 h (a), 16h (b) and 24h (c) after DL-152 injection.
Table II Cell yield and plating efficiency for KHT tumours excised from control
or irradiated mice. Tumours were removed after sacrifice by cervical fracture
(aerated) or 15 min after sacrifice after nitrogen asphyxiation (hypoxic)
cellsg 1 Plating
tumour x 10- 7 efficiency % Surviving
Drug treatment Radiation +s.e. +s.e. fraction
- Aerated 1.4+0.19 12.2+2.1 1.0
- Hypoxic 1.64+0.28 10.1 +2.0 1.0
None
25.0Gy Aerated 1.57+0.14 0.027+0.005 0.0020+0.0003
25.0Gy Hypoxic 1.38+0.13 0.20+0.004 0.0198+0.01
Aerated 0.49+0.1 L 5.9+0.9 1.0
DL-152 - Hypoxic 0.18+0.06 4.1 +0.7 1.0
320mgkg-1
16h before 25.0Gy Aerated 0.56+0.15 0.0071 +0.0013 0.0012+0.0002
tumour excised 25.0Gy Hypoxic 0.14+0.05 0.090+0.015 0.022+0.010
does not differ significantly from that for non-drug
treated tumours (by the same criteria as above),
however the Surviving Fraction for drug-treated
aerated cells is significantly less than that for non-
drug treated cells (P<0.05) with the result that the
calculated hypoxic fraction for drug-treated
tumours is less than that of control. If these
changes were the result of an increased
radiosensitivity for drug-treated hypoxic cells the
extent of the change would presumably be radiation
dose-dependent. In fact the ratio of Surviving
Fractions remains quite constant over the dose
range 15-30 Gy (Figure 4(b)). The most likely
explanation of these observations is that the
proportion of hypoxic cells in the tumour has been
reduced during 16h exposure to the drug.
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The fact that the hypoxic fraction is reduced
between 8 and 24h post-injection and possibly for a
longer period suggests that for combined treatment
of tumours with DL-152 and radiation, the most
effective protocol would schedule radiation
treatment for the post-injection period when the
hypoxic fraction is minimal. Experiments are being
done to determine the effectiveness of combined
treatment at these times.
I am indebted to N. Twyman, D. Giambattista and D.
Ivancic for excellent technical assistance.
These investigations were supported by the National
Cancer Institute of Canada.
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